Aaron Goodman Highlights IL18-Secreting CAR T Therapy for Refractory Lymphoma
Aaron Goodman, Hematologist/Oncologist and an Associate Professor of Medicine at the University of California, shared a post on X:
“This is pretty cool and amazing! Anti-CD19 CART that secretes IL18. 3-day manufacturing process! 50% durable CR in patients with refractory lymphoma who had prior anti-CD19 CAR T. Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure | NEJM.”
Title: Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure
Authors: Jakub Svoboda, Daniel J. Landsburg, James Gerson, Sunita D. Nasta, Stefan K. Barta, Elise A. Chong, Michael Cook, Noelle V. Frey, Joanne Shea, Amanda Cervini, Amy Marshall, Megan Four, Megan M. Davis, Julie K. Jadlowsky, Anne Chew, Edward Pequignot, Vanessa Gonzalez, Julia Han Noll, Luca Paruzzo, Juliana Rojas-Levine, Gabriela Plesa, John Scholler, Donald L. Siegel, Bruce L. Levine, David L. Porter, Saba Ghassemi, Marco Ruella, Andrew Rech, Rachel M. Leskowitz, Joseph A. Fraietta, Wei-Ting Hwang, Elizabeth Hexner, Stephen J. Schuster, Carl H. June
Read the Full Article on NEJM.
More posts featuring Aaron Goodman.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023